Jennifer A Shin1, Amanda Parkes2, Areej El-Jawahri3, Lara Traeger4, Helen Knight5, Emily R Gallagher3, Jennifer S Temel3. 1. Division of Hematology & Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA jashin@partners.org. 2. MD Anderson Cancer Center, Houston, TX, USA. 3. Division of Hematology & Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA. 4. Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. 5. Johns Hopkins School of Medicine, Baltimore, MD, USA.
Abstract
BACKGROUND: Hospitalizations in patients with metastatic cancer occur commonly at the end of life but have not been well-described in individuals with metastatic breast cancer. AIM: To describe the reasons for admission and frequency of palliative care and hospice utilization in hospitalized patients with metastatic breast cancer. DESIGN: This was a retrospective chart review of patients who had their first hospitalization with a diagnosis of metastatic breast cancer between 1 January 2009 and 31 December 2010. To standardize follow-up time, we collected data for 3 years post the index hospitalization. SETTING/PARTICIPANTS: We identified 123 consecutive patients who were hospitalized for the first time with a diagnosis of metastatic breast cancer at a single, tertiary care center. RESULTS: Uncontrolled symptoms accounted for half (50%, 62/123) of index admissions. The majority of patients died during the follow-up period (76%, 94/123), and the median time from index admission to death was 6 months (range: 0-34 months). Approximately half (53%, 50/94) died in the hospital or within 14 days of last hospital discharge, and less than one-third (29%, 27/94) were referred to hospice after their last hospitalization. The inpatient palliative care team evaluated 57% (54/94) of those who died at least once during an admission, but only 17% (16/94) of patients attended an outpatient palliative care appointment. CONCLUSIONS: Hospitalized patients with metastatic breast cancer are commonly admitted for uncontrolled symptoms and have a poor prognosis. However, only a minority receive outpatient palliative care or are referred to hospice during their last hospitalization prior to death.
BACKGROUND: Hospitalizations in patients with metastatic cancer occur commonly at the end of life but have not been well-described in individuals with metastatic breast cancer. AIM: To describe the reasons for admission and frequency of palliative care and hospice utilization in hospitalized patients with metastatic breast cancer. DESIGN: This was a retrospective chart review of patients who had their first hospitalization with a diagnosis of metastatic breast cancer between 1 January 2009 and 31 December 2010. To standardize follow-up time, we collected data for 3 years post the index hospitalization. SETTING/PARTICIPANTS: We identified 123 consecutive patients who were hospitalized for the first time with a diagnosis of metastatic breast cancer at a single, tertiary care center. RESULTS: Uncontrolled symptoms accounted for half (50%, 62/123) of index admissions. The majority of patients died during the follow-up period (76%, 94/123), and the median time from index admission to death was 6 months (range: 0-34 months). Approximately half (53%, 50/94) died in the hospital or within 14 days of last hospital discharge, and less than one-third (29%, 27/94) were referred to hospice after their last hospitalization. The inpatient palliative care team evaluated 57% (54/94) of those who died at least once during an admission, but only 17% (16/94) of patients attended an outpatient palliative care appointment. CONCLUSIONS: Hospitalized patients with metastatic breast cancer are commonly admitted for uncontrolled symptoms and have a poor prognosis. However, only a minority receive outpatient palliative care or are referred to hospice during their last hospitalization prior to death.
Authors: Elizabeth H Bradley; Holly Prigerson; Melissa D A Carlson; Emily Cherlin; R Johnson-Hurzeler; Stanislav V Kasl Journal: Am J Psychiatry Date: 2004-12 Impact factor: 18.112
Authors: Monica Beccaro; Massimo Costantini; Paolo Giorgi Rossi; Guido Miccinesi; Maria Grimaldi; Paolo Bruzzi Journal: J Epidemiol Community Health Date: 2006-05 Impact factor: 3.710
Authors: Gabrielle B Rocque; Anne E Barnett; Lisa C Illig; Jens C Eickhoff; Howard H Bailey; Toby C Campbell; James A Stewart; James F Cleary Journal: J Oncol Pract Date: 2013-01 Impact factor: 3.840
Authors: Thomas J Smith; Sarah Temin; Erin R Alesi; Amy P Abernethy; Tracy A Balboni; Ethan M Basch; Betty R Ferrell; Matt Loscalzo; Diane E Meier; Judith A Paice; Jeffrey M Peppercorn; Mark Somerfield; Ellen Stovall; Jamie H Von Roenn Journal: J Clin Oncol Date: 2012-02-06 Impact factor: 44.544
Authors: Lisa D DiMartino; Bryan J Weiner; Laura C Hanson; Morris Weinberger; Sarah A Birken; Katherine Reeder-Hayes; Justin G Trogdon Journal: J Palliat Med Date: 2017-08-03 Impact factor: 2.947
Authors: Joseph A Greer; Beverly Moy; Areej El-Jawahri; Vicki A Jackson; Mihir Kamdar; Juliet Jacobsen; Charlotta Lindvall; Jennifer A Shin; Simone Rinaldi; Heather A Carlson; Angela Sousa; Emily R Gallagher; Zhigang Li; Samantha Moran; Magaret Ruddy; Maya V Anand; Julia E Carp; Jennifer S Temel Journal: J Natl Compr Canc Netw Date: 2022-02 Impact factor: 11.908
Authors: Laura C Hanson; Natalie C Ernecoff; Kathryn L Wessell; Feng-Chang Lin; Matthew I Milowsky; Frances A Collichio; William A Wood; Donald L Rosenstein Journal: J Pain Symptom Manage Date: 2020-10-20 Impact factor: 3.612
Authors: Marijanne Engel; Annemieke van der Padt-Pruijsten; Auke M T Huijben; T Martijn Kuijper; Maria B L Leys; Annemieke Talsma; Agnes van der Heide Journal: Eur J Cancer Care (Engl) Date: 2021-10-26 Impact factor: 2.328